763113-22-0 | Olaparib (C₂₄H₂₃FN₄O₃)

Chemical type

• Synthetic small molecule

^[1]

• PARP inhibitor (Poly ADP-ribose polymerase inhibitor)
• Small-molecule targeted anticancer drug

^[2]

Key properties

• Inhibits poly (ADP-ribose) polymerase (PARP)
• Antitumor effects, particularly in cancers with BRCA1 or BRCA2 mutations

^[1]

• Inhibits PARP-1 and PARP-2 enzymes
• Induces synthetic lethality in cells with homologous recombination repair (HRR) deficiency
• Strong PARP-trapping activity
• Orally active targeted therapy
• Effective particularly in BRCA-mutated cancers

^[2]

• Treatment of breast cancer and ovarian cancer
• Screened in study as a potential multi-target SARS-CoV-2 antiviral

^[1]

• Treatment of metastatic castration-resistant prostate cancer (mCRPC)
• Treatment of BRCA1/2-mutated cancers
• Used as monotherapy or in combination therapy

^[2]

Classification by use

• Anti-cancer agent
• Antiviral agent (investigational)

^[1]

• Chemicals used as targeted anticancer agents
• Chemicals used as PARP inhibitors
• Chemicals used in precision oncology
• Chemicals used in DNA repair–deficient cancer therapy

^[2]

A trustworthy factory and manufacturer

Demei Chemical Technology Co., Ltd. is a modern high-tech enterprise integrating R&D, production, and sales. The company's founder, Dr. Arron, born in April 1975, graduated from the School of Mechanical Engineering at Yanshan University and has been engaged in research in the fields of mechanical engineering and chemical synthesis for many years. The company's products focus on the chemical industry, primarily dealing in chemical raw materials and chemical production machinery and equipment. With its strong technical capabilities, advanced production equipment, and strict quality management system, the company has earned the trust of customers worldwide.

1. [Cite:2] Multi-target direct-acting SARS-CoV-2 antivirals against the nucleotide-binding pockets of virus-specific proteins, Virology, Volume 577, December 2022, Pages 1-15
2. [Cite:2] PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-analysis, European Urology Open Science, Volume 84, February 2026, Pages 1-12